Hematopoietic stem cell softening mediates mobilization due to AMD3100, thereby increasing count in peripheral blood by Laohapant, Alvin
HEMATOPOIETIC STEM CELL SOFTENING MEDIATES 
MOBILIZATION DUE TO AMD3100, THEREBY INCREASING 



























In Partial Fulfillment 
of the Requirements for the Degree 
B.S. in Biomedical Engineering with the Research Option  








Georgia Institute of Technology 
May 2017 
HEMATOPOIETIC STEM CELL SOFTENING MEDIATES 
MOBILIZATION DUE TO AMD3100, THEREBY INCREASING 























Dr. Wilbur Lam, Advisor 
School of Biomedical Engineering 
Georgia Institute of Technology 
 
Dr. Linda Harley 
School of Biomedical Engineering 











 I would like to thank everyone in the Lam Lab at Georgia Tech, especially my 
graduate student mentor, Meredith Fay, and principal investigator, Dr. Wilbur Lam, for 
their support, assistance and mentorship towards the completion of not only this thesis, 

















TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS iii 
LIST OF FIGURES v 
LIST OF SYMBOLS AND ABBREVIATIONS vi 
SUMMARY vii 
CHAPTER 
1 Introduction 1 
2 Literature Review 3 
Background on Hematopoietic Stem Cells 3 
Effects of G-CSF and AMD3100 3 
Mechanical Properties of White Blood Cells 5 
Research Goals and Objectives 6 
3 Materials and Methods 7 
Biophysical Flow Cytometers 7 
Hematopoietic Stem Cells 8 
Low Cell Count BFC Protocol 8 
Data Analysis 9 
4 Results and Discussion 11 
Results 11 
Discussion 12 




LIST OF FIGURES 
Page 
Figure 1: Biophysical flow cytometry device 8 
Figure 2: Detailed view of the microfluidic capillary bed model 10 








LIST OF SYMBOLS AND ABBREVIATIONS 
 
HSCs  Hematopoietic Stem Cells  
WBCs  White Blood Cells 
RBCs  Red Blood Cells 












 Hematopoietic stem cells (HSCs) have the ability to differentiate into any blood 
cell as well as self-renew, giving rise to their pluripotent attribute. With the ability to 
differentiate, HSCs have the potential to be transplanted from healthy donors to matched 
patients with hematological malignancies as well as bone marrow failure. While the bulk 
of HSCs are located within the bone marrow, mobilization into the peripheral blood is 
required for accessible collection of HSCs, which ultimately eliminates the need for 
surgical procedures. Previous research findings have found that hematopoietic growth 
factor cytokines, more specifically Granulocyte colony-stimulating factor (G-CSF), as 
well as the mobilizing agent, plerixafor (AMD3100) increase mobilization of HSCs into 
the peripheral blood. While G-CSF and AMD3100 have both been scientifically proven 
and approved to increase HSC mobilization, the mechanical properties of HSCs have yet 
to be observed when mobilizing from the bone marrow to the peripheral blood. Here we 
use HSCs flowing through a microfluidic model to represent mobilization and hope to see 
cell softening due to AMD3100 during transit through the microfluidic device. By 
investigating the mechanical properties of HSCs during mobilization in the presence of 
AMD3100, clinical significance can lead to further studies as well as alternative 
mobilization techniques for use with HSC transplantation for patients with hematological 









 Hematopoietic stem cells (HSCs) have the ability to differentiate into any blood 
cell as well as self-renew, giving rise to their pluripotent attribute. HSCs are able to 
differentiate into white blood cells (WBCs) or leukocytes, lymphoid cells, red blood cells 
(RBCs) or erythrocytes, and platelets. In order to form the aforementioned blood cells, 
HSCs must undergo a process termed hematopoiesis within the bone marrow where 
specific progenitor cells dictate the pathway which the HSCs will take to becoming a 
specific blood cell (Kohn, Nolta, & Crooks, 2001).  
 With the ability to differentiate, HSCs have the potential to be transplanted from 
healthy donors to matched patients with hematological malignancies as well as bone 
marrow failure. While the bulk of HSCs are located within the bone marrow, 
mobilization into the peripheral blood is required for accessible collection of HSCs, 
which ultimately eliminates the need for surgical procedures. Under normal conditions, 
HSCs within the peripheral blood increase during stressful conditions such as 
inflammation or bleeding. Previous research findings by Motabi and DiPersio have found 
that hematopoietic growth factor cytokines, more specifically Granulocyte colony-
stimulating factor (G-CSF), as well as the mobilizing agent, plerixafor (AMD3100) 
increase mobilization of HSCs into the peripheral blood. G-CSF is an approved cytokine 
that alters the HSC niche, or microenvironment, within the bone marrow and activates 
proliferation preceding mobilization (Motabi & DiPersio, 2012). On the other hand, 
AMD3100 is a bicyclam molecule that acts as a reversible antagonist of CXCR4, a 
receptor for stromal derived factor-1 (SDF-1), which ultimately inhibits SDF-1 to 
CXCR4 binding and leads to SDF-1 down regulation (Devine et al., 2008). Recently, 
clinical WBC count has been shown by Fay et al. at the Lam Lab at the Georgia Institute 
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of Technology to increase via softening due to glucocorticoid and catecholamine 
hormones which aids in demargination and trafficking. Since, WBCs ultimately stem 
from HSCs, the research findings provide significance to the mechanical properties of 
HSCs during mobilization from the bone marrow to the circulating peripheral blood (Fay 
et al., 2016). 
 While G-CSF and AMD3100 have both been scientifically proven and approved 
to increase HSC mobilization, the mechanical properties of HSCs have yet to be observed 
when mobilizing from the bone marrow to the peripheral blood. Following recent 
findings relating to leukocytes and questions related to whether changes in mechanical 
properties affect mobilization, HSC stiffness is explored during mobilization when 
exposed to G-CSF and AMD3100. A reason for not researching HSC mechanical 
properties during mobilization, as of yet, may stem from the fact that certain mobilizing 
agents are known to increase HSCs in the peripheral blood and therefore, knowing how 
HSCs themselves are affected during mobilization may not be of great importance. But, 
this gap in understanding may prevent discovery of alternatives to HSC mobilization and 
ultimately HSC transplantation. 
 By investigating the mechanical properties of HSCs during mobilization in the 
presence of G-CSF as well as AMD3100, clinical significance can lead to further studies 
as well as alternative mobilization techniques for use with HSC transplantation for 
patients with hematological malignancies as well as bone marrow failure. In addition, a 
purely mechanical result in increased mobilization will be observed as opposed to the 
currently accepted mechanisms of G-CSF and AMD3100, respectively.  Ultimately, a 
mechanical understanding of HSCs will allow for a greater understanding of 





Background on Hematopoietic Stem Cells 
 Before focusing on the process of HSC mobilization, self-renewal, differentiation, 
and proliferation of HSCs should be understood to develop a background understanding 
of the potential of HSCs as a form of treatment. Ogawa’s results from in vitro 
experiments confirm previous findings that self-renewal and differentiation can be 
represented as stochastic models, while cell survival and proliferation do not reflect a 
stochastic model, but are governed by various cytokines that can both stimulate and 
inhibit the process (Ogawa, 1993). Given that Ogawa’s paper is a review, detailed 
methods, results, and analysis techniques were not stated; only the overall conclusion 
from the experiments was described. Further experimentation down the line will be 
necessary to account for in vivo affects and technological advancements. Ogawa goes 
into detail about the mechanism and function of the cytokine, G-CSF, a factor that this 
research will be using in the experiments, allowing this study to understand the respective 
interactions at a cellular level when G-CSF is administered. While G-CSF interactions 
with HSCs are clearly understood, additional information regarding their mechanical 
properties in the presence of the cytokine is not. This gap in research is the focus of the 
current study. 
Effects of G-CSF and AMD3100 
 G-CSF, a cytokine, and AMD3100, a mobilizing agent, have been known to 
increase mobilization of HSCs into peripheral blood from previous studies, while also 
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being approved as a treatment method. Motabi and DiPersio present an overview of HSC 
mobilization and the results that AMD3100 affects adhesion and chemical gradients and 
therefore mobilizes HSCs within hours, while G-CSF affects the microenvironment and 
therefore requires days before mobilization of HSCs is observed (Motabi & DiPersio, 
2012). As reported by Motabi and DiPersio, the results stem from review of prior 
research findings without performing their own experiments, leading to the ability for 
future researchers to conduct experiments and confirm findings, similar to Ogawa. By 
understanding the effects of mobilization due to G-CSF and AMD3100, this research will 
be able to hypothesize that a change in hematopoietic stem cell mechanical properties 
will occur when exposed to the respective factor. In addition, the review mentions 
multiple dosages and time scales patients were exposed to which allows for this research 
to establish a range of parameters that will be used to treat the hematopoietic stem cells 
for this experiment. According to Azab et al., AMD3100 is shown to increase apoptosis 
when bone marrow stromal cells are present, to inhibit adhesion, and to limit CXCR4 
expression temporarily before returning to steady state. From in vivo studies, AMD3100 
was shown to mobilize myeloma cells and have increased sensitivity and to aid in the 
reduction of tumors (Azab et al., 2009). While the paper focuses on multiple myeloma 
cells more than HSCs, AMD3100 and other drugs were used on HSCs in a small portion 
of the paper. Seeing that HSC mobilization has minimally been tested, this creates a gap 
in research that will be potentially covered by the findings from the current research. 
Devine et al. conducted a pilot trial for hematopoietic stem and progenitor cells 
mobilization via AMD3100 only to inhibit CXCR4 interactions. From the trial, Devine et 
al. holds the view that AMD3100 increased mean white blood cell count about 3-fold, 
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while the median CD34 count increased 8-fold (Devine et al., 2008). From Devine et al.’s 
results, it may follow that mechanical properties of HSC can be studied to determine if a 
change exists when traversing from the bone marrow to the peripheral blood, giving rise 
to the research goals. 
Mechanical Properties of White Blood Cells 
 Previous research from the Lam Lab at the Georgia Institute of Technology and 
Emory University has revealed that glucocorticoids and catecholamine hormones 
increase clinical white blood cell count via softening due to demargination and 
trafficking. As Fay et al. states, glucocorticoids and catecholamines cause leukocyte 
demargination in vessels due mostly to mechanical properties using ex vivo, in vitro, and 
computational experiments. Through demargination and softening, an increase in white 
blood cell count is observed in the complete blood count. Using two different 
microfluidic models, transit times are observed and compared to determine that a faster 
time suggests deformation while the positioning of the leukocyte in the “vessel” shows 
demargination, respectively (Fay et al., 2016). The research findings provide significance 
to the mechanical properties of HSCs during mobilization from the bone marrow to the 
circulating peripheral blood due to the fact that WBCs ultimately stem from HSCs. While 
this paper focuses on leukocytes, the same type of experiment will be performed on 
hematopoietic stem cells since this study will be an extension of this paper. Fay et al. 
provides a very detailed paper consisting of various methods to affirm the findings of the 
research, which the research will be following to an extent with the addition of 
AMD3100 and G-CSF as treatment options. Seeing that leukocyte stiffness decreases 
when exposed to certain drugs in order to travel through vessels quicker, this yields a 
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basis for this experiment since hematopoietic stem cells need to mobilize from the bone 
marrow. Therefore, this paper is significant because it sets up the possibility of research. 
Research Goals and Objectives 
 Overall, the current study will address the gap in understanding of hematopoietic 
stem cell mechanical properties during mobilization under normal conditions as well as 
under treatment from AMD3100 and G-CSF. The current study will determine 
mechanical properties of HSCs using microfluidic models, various microscopy 
techniques, and flow cytometry to confirm findings. By investigating the mechanical 
properties of HSCs during mobilization in the presence of G-CSF as well as AMD3100, 
clinical significance can lead to further studies as well as alternative mobilization 
techniques for use with HSC transplantation for patients with hematological malignancies 
as well as bone marrow failure. In addition, a purely mechanical result in increased 
mobilization will be observed as opposed to the currently accepted mechanisms of G-
CSF and AMD3100, respectively. Ultimately, a mechanical understanding of HSCs will 
allow for a greater understanding of hematopoiesis and mobilization. 
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CHAPTER 3 
MATERIALS AND METHODS 
 
 In order to observe and characterize mechanical properties associated with the 
stiffness of HSC, biophysical flow cytometry was used (Rosenbluth, Lam, & Fletcher, 
2008). By using the microfluidic-based biophysical flow cytometry, single cell HSC 
stiffness during mobilization into the peripheral blood was characterized by the transit 
time of each cell through the capillary bed model of the microfluidic device under in vitro 
conditions.  
Biophysical Flow Cytometers 
 Biophysical flow cytometry devices (Figure 1) with 5.9 ± 0.8 µm-wide channels 
were fabricated following the method outlined by Rosenbluth, Lam, & Fletcher. In short, 
PDMS mixed from a Sylgard 184 Silicone Elastomer Kit was molded to a mask formed 
via typical microfabrication techniques and then cut out. Prior to being bonded to a 22 x 
40mm cover glass slide (Corning) using a plasma cleaner (Harrick Plasma PDC-32G), 
inlet and outlet holes were punched into the device. The microfluidic device was then 
blocked with 10% Bovine Serum Albumin (BSA) (Sigma-Aldrich) in 1x Phosphate 
Buffered Saline (PBS). 
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Figure 1. Biophysical flow cytometry device. The microfluidic capillary bed model 
consists of channels that are 5.9 ± 0.08 µm wide, which are smaller than the average 
diameter of hematopoietic stem cells (HSCs). Using a mold developed via soft 
lithography, Polydixmethylsilane (PDMS) was poured onto the mold and cured at 60 ˚C. 
The device was then cut from the mold, inlet and outlet holes were poked through the 
device and then bonded to coverslips using a plasma cleaner. At least 1 hour before use, 
the device was blocked using a 10% bovine serum albumin in phosphate buffered saline 
solution. 
Hematopoietic Stem Cells 
 Hematopoietic stem cells from mice were provided by the Cheng-Kui Qu Lab 
within the Cancer Cell Biology Program at the Winship Cancer Institute at Emory 
University. HSCs were treated with AMD3100 octahydrochloride (Sigma) and G-CSF 
human, recombinant (Sigma). 
Low Cell Count BFC Protocol 
 Due to the availability and concentration of mice HSCs, the protocol for 
conducting the flow cytometry experiments outlined by Rosenbluth, Lam, & Fletcher 
could not be followed; therefore, a low cell count protocol for biophysical flow 
cytometers was developed. About 2,000 HSCs, a 2 µL dilution from a 1 x 106/1 mL 
sample of HSCs, were loaded into a pipet tip with microcapillary for loading gels (VWR) 
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and then inserted into the inlet of the microfluidic device. A 5mL Leur-Lok syringe (BD) 
with an attached 20GA x ½” needle (Techcon Systems) was then attached to the outlet of 
the device with thick tubing and then #30 AWG thin wall tubing (Cole-Parmer 
Instrument Company) and then locked onto a syringe pump (Harvard Apparatus PHD 
Ultra). Cells were then withdrawn through the device via the pump at a flow rate of 10 
µL/min and recorded via bright field microscopy with a 20x 0.45A air objective on a 
Nikon Eclipse TE2000-U and Qimaging Retiga EXi camera along with NIS Elements.  
Data Analysis 
 Transit times were then calculated manually from obtained flow video using NIS 
Elements (Figure 2). Differences in relative entrance and exit frames were calculated and 
then divided by the overall frames per second (FPS) to obtain respective transit times. 
Mann-Whitney tests at a 5% significance level were then conducted using MATLAB to 
determine statistical significance between respective transit times between untreated and 
treated cells. Relative frequency within specific transit times were then plotted for both 




Figure 2. Detailed view of the microfluidic capillary bed model. The smallest channels 
have a width of 5.9 ± 0.08 μm. Once flow is applied by withdrawing HSCs through the 
device using a syringe pump, cells traverse through the microfluidic capillary bed model 
in the direction of flow. Stuck cells can be identified as those that remain at the inlet of 
the smallest channel for a period greater than 10 seconds and traversing cells as those that 
are moving through the channels. Brightfield videos of the experiment were recorded and 
then manually analyzed to determine transit times over a set distance, indicated above. A 
faster transit time would therefore indicate a more deformable, or softer, HSC suggesting 






RESULTS AND DISCUSSION 
 
Results 
To determine whether mechanical properties of HSCs are altered during treatment 
to mediate mobilization, biophysical flow cytometry experiments were conducted to 
eliminate confounding variables that may exist otherwise. The microfluidic system is a 
capillary bed model within the microvasculature with channel widths that are smaller 
than the average diameter of HSCs; changes in mechanical properties are determined by 
transit time changes due to deformation of the HSCs. 
Given the difficulty in obtaining HSCs for this research, results were obtained 
from experiments using AMD3100 as the only treatment, leaving G-CSF yet to be tested 
as a treatment condition. Flow videos were recorded for both untreated negative control 
HSCs and HSCs treated with AMD3100 at a concentration of 40µM. Upon manually 
calculating relative transit times for both the control HSCs and AMD3100 treated HSCs, 
a Mann-Whitney test was conducted and found to yield a p < 0.05 (Figure 3). 
Additionally, HSCs treated with AMD3100 had a higher frequency of lower transit times 
through the microfluidic channels versus control where a larger portion of HSCs had 
longer transit times. HSCs treated with AMD3100 were observed to traverse the channels 
with a significantly faster transit time, with a smaller portion of cells becoming stuck 
within the channels when compared to untreated HSCs. 
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Figure 3. Histogram comparing transit times of HSCs. Upon obtaining relative transit 
times for both control and AMD3100 conditions, a Mann-Whitney test was conducted 
using MATLAB. Compared to control, AMD3100 treated HSCs traversed the 
microfluidic capillary bed channels significantly faster with p < 0.05 and were less likely 
to be stuck at the inlet of the capillary channel. This indicates that AMD3100 mediated 
cellular softening due to observed deformation through faster transit times and a decrease 




This research shows that HSCs treated with hematopoietic growth factor 
cytokines, specifically AMD 3100, have shorter transit times when traversing through the 
microfluidic channels. Shorter transit times indicate that the HSCs are becoming less 
stuck within the channels and are traversing through the channels faster. As a result, this 
indicates changes to the mechanical properties of the HSCs as the cells are becoming 
softer through a decrease in the cellular stiffness. Additionally, since changes to the 
stiffness of HSCs are observed when treated with approved mobilizing agents, this may 
shed light to the initial mechanism by which HSCs are mobilized into the peripheral 
blood through changes in the cells’ mechanical and physical properties. 
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Similarly, the cytoskeleton of leukocytes has previously been shown to soften due 
to glucocorticoids, like dexamethasone, and catecholamines, like epinephrine. Using a 
similar biophysical flow cytometry method, additional microfluidic systems, as well as 
computational modelling, decreased cell stiffness and increased demargination have 
shown to directly increase clinical CBC (complete blood count). This parallel between 
leukocyte and HSC softening may indicate that softening of the cytoskeleton of blood 




CONCLUSION AND FUTURE WORK 
 
  AMD3100 has been approved by the FDA to increase HSC mobilization, but the 
mechanical properties of HSCs have yet to be studied until now. Through biophysical 
flow cytometry using microfluidic systems, mechanical properties of HSCs have been 
observed to be altered through cellular softening when treated with a mobilizing agent. 
This indicates that during mobilization, HSCs may undergo changes to the cytoskeleton 
which allows for their mobilization into the peripheral blood. By investigating the 
mechanical properties of HSCs during mobilization, clinical significance can lead to 
additional studies and the discovery of novel mobilization techniques for use with HSC 
transplantation for patients with hematological malignancies.  
 While this research has identified HSC softening due to AMD3100, a mobilizing 
agent, additional studies will need to be conducted for G-CSF treatments as well. 
Additionally, atomic force microscopy will also need to be conducted to obtain numerical 
cell stiffness values for control HSCs, AMD3100, and G-CSF treated HSCs. These 
values will then allow for the direct statistical comparison of how cellular stiffness is 
altered and to what degree by the hematopoietic growth factor cytokines. Finally, human 
subject testing through ingestion of AMD3100 and G-CSF will need to be conducted to 
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